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ABSTRACT

OBJECTIVE: The objective of this selective EBM review is to determine whether or not
lubiprostone is effective in treating symptoms of chronic constipation.
STUDY DESIGN: Review of three English language primary randomized controlled trials from
2007- 2010.
DATA SOURCES: Three double-blind, randomized, controlled trials were found using PubMed.
These studies compared treatment with lubiprostone to a visually matched placebo.
OUTCOME MEASURED: The frequency of each patient’s spontaneous bowel movements
within the first 24 hours after initial treatment was recorded from the data collected from the
patient’s daily diary.
RESULTS: All three trails demonstrated a statistically significant improvement in the rates of
spontaneous bowel movements in patients with chronic constipation receiving treatment with
lubiprostone compared to those receiving the placebo.
CONCLUSIONS: Based on theses three trials, lubiprostone is effective in treating symptoms of
chronic constipation.
KEY WORDS: chronic constipation, lubiprostone
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INTRODUCTION
Chronic constipation is a condition that adversely affects the daily lives of many men and

women. The condition is defined as less than 3 spontaneous bowel movements (SBMs) per
week, in addition to symptoms of constipation associated with 25% of bowel movements over
the past 6 months.1 Although chronic constipation is more prevalent in the elderly population, it
does affect all age groups. In the United States prevalence rates for chronic constipation range
from 12–19%, with women being affected twice as often as men.2 Furthermore, symptoms of
constipation result in a decreased quality of life, reduced productivity and an increase in the
number of missed work or school days. This leads to constipation being among one of the most
frequent patient complaints faced by internists and primary care physicians, in addition to
accounting for nearly 50% of referrals to gastroenterologists.1
As one of the most common digestive complaints in the general population, constipation
is also associated with substantial economic costs. Each year more than 2.5 million Americans
visit their healthcare provider for relief from constipation.3 The estimated total medical cost of
care for patients with constipation in 2001 was $235 million per year, with 55% from inpatient
care, 23% from the Emergency Department, 16% from outpatient physicians and 6% from
outpatient hospital settings.4 Therefore, not only is chronic constipation a burden on patients’
lives, but it is taxing on the healthcare system as well.
There are many underlying causes of chronic constipation. However, the condition
generally results from inadequate fiber or fluid intake, from impaired colonic transit or anorectal
dysfunction.2 Also, symptoms of constipation can vary from patient to patient making it difficult
for practitioners to clinically quantify the severity of the condition. Symptoms generally include
difficult or infrequent bowel movements, excessive straining, hard stools, lower abdominal
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fullness or a sense of incomplete evacuation.2 Due to the difficulty evaluating constipation,
clinicians determine severity by focusing on the quantitative frequency of a patient’s bowel
movements via the use of patient daily dairies. The information gathered from the diary does not
only help assess the degree of constipation, but can also help guide patient treatment.
There are multiple home and pharmacologic remedies for treating constipation. The initial
step in treatment usually involves lifestyle and dietary modifications. Lifestyle changes include
increasing fluid intake, exercising and establishing a regular bowel movement routine. Dietary
changes mainly focus on increasing fiber intake. This can cause stool to bulk leading to colonic
dilation that promotes intestinal peristalsis.3 If lifestyle and dietary modifications fail, bulk
laxatives are generally the next choice. Bulk forming laxatives include psyllium, methycellulose,
polycarbophil and wheat dextrin.3 These are polysaccharide or cellulose derivatives that act by
absorbing water and increasing fecal mass.3 If patients have no response to bulk laxatives,
osmotic laxatives are the next step in treatment. Osmotic laxatives include polyethylene glycol,
lactulose, sorbitol and magnesium hydroxide.3 If these all fail, lubiprostone has shown
considerable promise with patients suffering from chronic constipation.1 As a side note,
stimulant laxatives are effective in relieving acute symptoms of constipation, but should be
avoided in cases of chronic constipation due to adverse affects with long term use such as
dehydration and electrolyte disturbances.3
This review evaluates three double blind, randomized, controlled trials comparing the
efficacy of lubiprostone in treating symptoms of chronic constipation. As previously stated,
lubiprostone may be used as treatment for severe chronic constipation that is not relieved by
other treatment alternatives. Lubiprostone has been shown to accelerate small intestine and
colonic transit by activating chloride channels in the intestinal epithelial cells.5 When activated,
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these cells contribute to the secretion of intestinal fluid causing an increase in luminal water
content without significantly accelerating the rate of ascending colon emptying.5 This ultimately
results in relief of constipation.
OBJECTIVE
The objective of this systematic review is to determine whether or not lubiprostone is
effective in treating symptoms of chronic constipation.
METHODS
Three double-blind, randomized, controlled trials (RCTs) that included healthy men and
women greater than 18 years of age with history of chronic constipation, defined as less than 3
SBMs per week, in addition to symptoms of constipation associated with 25% of bowel
movements over the past 6 months were selected for study.1,5,6 All three studies showed no
significant differences in demographic parameters between the treatment and placebo groups.
The population in each study was predominately female Caucasians with the mean age ranging
between 46-48 years.1,5,6 Also, the inclusion and exclusion criteria of all three studies were
similar. Additionally, discontinuation rates were not substantially different between the treatment
and placebo groups for each study used. These demographics and characteristics are
demonstrated in Table 1. All three studies compared the experimental group, receiving treatment
of lubiprostone 24mcg twice daily, to a control group, receiving a visually matched placebo. The
occurrence of a SBM within the first 24 hours of the initial treatment dose was compared among
experimental and control groups to determine the outcome of the studies.
All three articles used in this review were collected via PubMed database in 2014. The
key words used to acquire the articles were “lubiprostone” and “constipation.” Each article used
was published in English by peer reviewed journals between the years 2007 and 2010. All

	
  
	
  

	
   MacDonald,	
  Lubiprostone	
  &	
  Constipation	
  	
   4	
  

articles were POEMS selected based on their outcome’s relevance and importance to patients’
quality of life.
The inclusion criteria were synonymous for each RCT. The defined criteria consisted of
males or non-pregnant, non-lactating females over the age of 18 years old with chronic
constipation. 1,5,6 Symptoms used to define constipation included abdominal bloating or
discomfort, hard or very hard stools, sensation of incomplete evacuation or straining with
defecation.1,5,6 Additionally, potential participants less than 50 years old must have had a flexible
sigmoidoscopy or colonoscopy performed within the last 5 years and patients over 50 years old
were required to have a barium enema with flexible sigmoidoscopy or a colonoscopy to rule out
organic disorders of the large bowel prior to being considered.1,5,6
Exclusion criteria were also similar for each article. The exclusion criteria consisted of
documented mechanical obstruction, megacolon or a diagnosis of pseudo-obstruction. Also,
known or suspected organic disorders of the large or small intestine, secondary causes of
constipation, hospitalization for any gastrointestinal or abdominal surgical procedure during the
3 months prior to study initiation and any history of prior bowel resection excluded patients from
participating in any of the studies.1,5,6 In addition, the studies performed by Johanson et al and
Johanson and Ueno excluded patients with clinically significant cardiovascular disease, liver,
lung or other systemic disease.5,6 Johanson et al went further to exclude patients with
hematologic, urinalysis or blood chemistry abnormalities or diagnosis of cancer within the past 5
years.5 Furthermore, the study by Johanson and Ueno also excluded HIV positive patients.6
Statistics were reported based on p-values using dichotomous data. A Cochran-MantelHaenszel test was used to adjust for a pooled center and determine if there was a consistent
difference in the percentage of patients who experienced a SBM within 24 hours of initial
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treatment between the experimental and control groups.1 Control event rate (CER) and
experimental event rate (EER) were used to calculate relative benefit increase (RBI), absolute
benefit increase (ABI), relative risk increase (RRI) and absolute risk increase (ARI). ABI was
then used to determine number needed to treat (NNT) and ARI was used to determine numbers
needed to harm (NNH).
Table1: Demographics and characteristics of included studies
Study

Type

# Pts

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

237

Age
(yrs)
≥18

Barish1
(2010)

RCT

History of chronic
constipation.
Constipation
symptoms a/w at
least 25% of BM
≥6 months.
Sigmoidoscopy or
colonoscopy within
the last 5 years if
<50yrs, required if
≥50 yrs.

Mechanical obstruction,
megacolon/megarectum or
a diagnosis of pseudoobstruction. Organic
disorders of the large or
small intestine, secondary
causes of constipation,
hospitalization for any GI
issue during the 3 months
prior to study initiation.
Prior bowel resection.

31

Lubiprostone 24
mcg capsules PO
BID

Johanson5
(2008)

RCT

242

≥18

Same as above
inclusion criteria

Same as above exclusion
criteria. Plus: Clinically
significant CVS disease,
liver, lung or other
systemic disease.
Hematologic, urinalysis or
blood chemistry
abnormalities or cancer
within the past 5 years.

20

Lubiprostone 24
mcg capsules PO
BID

Johanson6
(2007)

RCT

129

18-75

Same as above
inclusion criteria

Same as Johanson (2008)
exclusion criteria. Plus:
HIV positive.

11

Lubiprostone 24mcg/day; 48 mcg ⁄
day; 72 mcg ⁄ day

OUTCOMES MEASURED
Each of the three RCTs used in this review assessed the efficacy of lubiprostone on
improving symptoms of chronic constipation. Patients in each study were instructed to keep a
daily diary that recorded information about their bowel movements. This information included
timing, straining and consistency of stools, in addition to sensations of bloating and discomfort.

	
  
	
  

	
   MacDonald,	
  Lubiprostone	
  &	
  Constipation	
  	
   6	
  

Patients rated the consistency of each bowel movement using a five- point scale, with 0 equaling
very loose to 4 equaling very hard. Patients also used a five- point scale to rate their degree of
straining during each bowel movement, with 0 equaling no straining to 4 being very severe.
Sensations of bloating and discomfort were additionally measured using a five-point scale, with
0 being absent to 4 being very severe. Furthermore, the use of any constipation relieving
medication was recorded along with any adverse events.1,5,6
The daily average number of SBMs, average number of weekly SBMs and the percentage
of patients experiencing a SBM on day one of treatment were calculated from the information
provided in the patient diaries. The term “spontaneous bowel movement” in these cases was
defined as a bowel movement occurring without the use of constipation relieving medication.1,5,6
Moreover, the average level of straining during bowel movements, average stool consistency and
average degree of abdominal bloating and discomfort were also measured from the information
gathered from patients daily diaries. Also all adverse events were rated by the investigator based
on intensity and relationship to treatment.1,5,6 Although all these variables were assessed in the
three RCTs, the outcome specifically looked at in this analysis is the percentage of patients
experiencing a SBM within 24 hours of the initial treatment dose, which was determined based
on the information reported in the patients daily dairies.
RESULTS
All data from the studies used were reported as dichotomous data from which
calculations evaluating tolerability, adverse events, and treatment effects were computed. Each
of the RCTs looked at the efficacy of lubiprostone 24 mcg twice daily in producing a SBM
within 24 hours of patients taking the initial dose compared to patients taking a placebo. All
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studies were performed in outpatient settings over a 3-4 week period and relied on patients to
complete their daily bowel movement diaries.
The RCT performed by Barish et al, showed that out of the 119 lubiprostone-treated
patients that completed the study, 61.3% of them experienced a SBM within 24 hours of taking
their first dose, compared with 31.4% of the 118 placebo treated patients that completed the
study.1 This data shows a significantly higher percentage of patients treated with lubiprostone
having an overall shorter time to their first SBM versus the placebo patients (P<0.0001).1
Additionally, the RCT performed by Johanson et al in 2008 showed that out of the patients that
completed the study, 56.7% of the 106 lubiprostone-treated patients experienced a SBM within
24 hours of taking their first dose compared with 36.9% of the 118 placebo treated patients
(P=0.0024).5 Again this study shows a significantly higher percentage of lubiprostone treated
patients having a SBM within the first 24 hours compared to the control group. Furthermore, the
study by Johanson and Ueno showed that out of the 63 patients who completed the study, 59.4%
of the 30 lubiprostone-treated patients experienced a SBM within 24 hours of taking their first
dose compared with 27.3% of the 33 placebo treated patients (P=0.009).4 Overall, throughout all
three RCTs, the proportion of patients experiencing a SBM within the first 24 hours of the initial
treatment dose was higher than that of the control group (Chart 1).
Chart 1: Percentage of patients experiencing a SBM within 24 hrs of initial dose of study
medication
Percent	
  of	
  Pateints	
  

70	
  
60	
  
50	
  
40	
  

Lubiprostone	
  

30	
  

Placebo	
  

20	
  
10	
  
0	
  
RTC	
  1	
  

RTC	
  2	
  

RTC	
  3	
  

	
  
	
  

	
   MacDonald,	
  Lubiprostone	
  &	
  Constipation	
  	
   8	
  
In the study performed by Barish et al, 72 patients experienced an SBM within 24 hours

after initial treatment with lubiprostone, compared to 37 patients that were treated with the
placebo. This equates to a control event rate (CER) of 31.4% and an experimental event rate
(EER) of 61.3%, which yields a relative benefit increase (RBI) of 95.2% and an absolute benefit
increase (ABI) of 28.9%. Using ABI, the numbers needed to treat (NNT) was calculated to be 4,
meaning that a health care provider needs to treat 4 adult patients with chronic constipation with
24 mcg lubiprostone BID to have one additional patient experience a SBM within 24 hours of
initial lubiprostone treatment than compared to the placebo (Table 2). Barish et al also reports
that 106 patients experienced adverse effects. The reported adverse events varied from mild to
moderate, but none were considered serious, with the most common being gastrointestinal in
origin.1 In total, 47 patients from the experimental group and 22 from the control group reported
having gastrointestinal side effects. This yields a CER of 18.6% and an EER of 39.5% with a pvalue of 0.0006 as determined by the Fisher exact test. The relative risk increase (RRI) was
calculated to be 52.9% and the absolute risk increase (ARI) was 20.9%. Numbers needed to harm
(NNH) was calculated to be 5 from the equation 1/ARI, meaning for every 5 patients treated with
24 mcg lubiprostone BID, one more patient would experience an adverse event than the control
(Table 3).1
Table 2: Calculations for treatment from Barish et al1
CER
0.314

EER
0.613

RBI
0.952

ABI
0.289

NNT
4

P-vaule
0.0003

Table 3: Calculations for harm from Barish et al1
CER
0.183

EER
0.395

RR1
0.529

AR1
0.209

NNH
5

P-vaule
0.0006

In the RCT performed by Johanson et al, 60 patients experienced an SBM within 24
hours after initial treatment with lubiprostone, compared to 43 patients that were treated with the
placebo. This equates to a CER of 36.9% and an EER of 53.7%, which yields a RBI of 53.7%
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and an ABI of 19.8%. Using ABI, the NNT was calculated to be 6 patients (Table 4). In addition,
the percentage of patients experiencing one or more adverse effects was higher in the
experimental group compared to the control group. For instance, 102 patients from the
experimental group reported one or more adverse effects compared to 74 from the control group.
This yields a CER of 50.8% and an EER of 70% with a p-value of 0.0026 as determined by the
Fisher exact test. The RRI was calculated to be 37.7% and the ARI was 19.2%. NNH was
calculated to be 6 patients (Table 5).5
Table 4: Calculations for treatment from Johanson et al5
CER
0.369

EER
0.57

RBI
0.537

ABI
0.198

NNT
6

P-vaule
0.0024

Table 5: Calculations for harm from Johanson et al5
CER
0.508

EER
0.7

RR1
0.377

AR1
0.192

NNH
6

P-vaule
0.0026

Lastly, in the study by Johanson and Ueno, 18 patients experienced an SBM within 24
hours after initial treatment with lubiprostone, compared to 9 patients who were treated with the
placebo. This equates to a CER of 27.3% and an EER of 59.4%, which yields a RBI of 1.2% and
an ABI of 32.1%. Using ABI, the NNT was calculated to be 4 patients (Table 6). In addition, the
percentage of patients experiencing one or more adverse effects was higher in the experimental
group compared to the control group. For instance, 24 patients from the experimental group
reported one or more adverse effects compared to 13 from the control group. This yields a CER
of 39% and an EER of 75%. The calculated probability or p-value for the occurrence of at least
one adverse effect was determined to be 0.006 by the Cochran-Amitage test that assessed
whether the adverse effect occurred at a rate related to the dose of the study drug.6 The RRI was
calculated to be 92% and the ARI was 36%. NNH was calculated to be 3 patients (Table 7).6
Table 6: Calculations for treatment from Johanson and Ueno
CER
0.273

EER
0.594

RBI
0.012

ABI
0.321

NNT
4

Table 7: Calculations for harm from Johanson et Ueno

P-vaule
0.009
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EER
0.75

RR1
0.92

AR1
0.36

NNH
3

P-vaule
0.006

In the RTC performed by Barish et al, 206 out of 237 patients completed the study. Of
those, 11 patients were from the placebo group and 20 patients were from the experimental
group. Of the 31 patients that discontinued the study 16 were due to adverse effects, with only
one of those patients being from the placebo group. In this RCT, the adverse effects associated
with lubiprostone were not serious and included nausea, upper abdominal pain, dyspnea and
headache.1 In the study by Johanson et al, 20 patients out of 244 discontinued, of those 14 were
from the treatment group and 6 from the placebo group. The adverse effects reported were
similar to those from the Barish et al study. In the Johanson et al study, adverse effects were the
most common reason for discontinuation in the treatment group, whereas lack of efficacy and
lost to follow up were the most common reasons in the placebo group. Of the 10 patients who
discontinued due to adverse effects, only 1 patient was from the placebo group.5 In the RTC by
Johanson and Ureo, 9 patients discontinued the study out of 63 total patients. Of these, 2
experimental patients and 1 placebo patient were lost due to adverse effects, with the most
common being nausea.6 In all three studies, no clinically significant changes in laboratory values,
vitals signs or physical exam findings were noted. Therefore, it does not appear that adverse
effects diminish the overall tolerability of lubiprostone.1,5,6
DISCUSSION
Based the results of the RCTs used in this review, lubiprostone 24 mcg BID significantly
increases the probability of having an SBM within the first 24 hours of treatment. Each RTC
analyzed produced statistically significant results with p-values less than 0.05 and without any
significant outliers. This promotes the belief that lubiprostone is effective in relieving the
symptoms of chronic constipation.
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Despite the statistical significance of the results, there are some limitations to the RCTs

used in this review. For instance, patients were advised not to change their diet or lifestyle during
the studies. This could have had an underlying effect on the results depending on each patient’s
diet. For example, a diet high in fiber may produce different results than a diet high in refined
carbohydrates or fat. Also, there was no documentation of patients’ psychiatric/emotional states,
such as depression, anxiety or stress, which could have affected their symptoms of constipation.
Lubiprostone is currently marketed for the treatment of chronic constipation as well as
opioid induced constipation and treatment of constipation dominant irritable bowel. However,
there are contraindications for its use. Lubiprostone should be avoided in patients with severe
diarrhea, gastrointestinal obstructions, or patients with moderate or severe hepatic impairment. In
addition, the use of methadone concurrently with lubiprostone may potentially decrease its
efficacy in a dose-dependent manner.7 Luckily, lubiprostone is covered by most private
insurances, but only if alternative treatments have been exhausted. However, without insurance,
this drug is very expensive, costing $359.47 for a 1 month supply of lubiprostone 24 mcg BID.7
CONCLUSION
The results from the three double-blind, randomized, controlled trials used in this review
indicated that lubiprostone is effective in treating symptoms of chronic constipation. This
conclusion was reached based on the fact that compared with those randomized to the placebo
groups, patients given 24 mcg lubiprostone twice daily experienced a significantly higher
number of a SBMs within the first 24 hours of initial treatment. Given the high prevalence of
constipation along with decreased quality of life associated with this condition, the impact of
lubiprostone on treating chronic constipation proves clinically significant.5
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